Outcome of Board Meeting held on May 12, 2026
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Board approved FY26 audited financial results showing revenue growth of 3.2% YoY to Rs 335.9 billion, but Q4FY26 revenue declined 11.6% YoY to Rs 75.2 billion due to lower Lenalidomide sales and a Rs 4.5 billion Shelf Stock Adjustment. Profit after tax fell significantly - down 86% YoY in Q4 to Rs 2.2 billion and down 24% YoY for FY26 to Rs 42.9 billion. EBITDA margin compressed to 22.8% in FY26 from 28.3% in FY25. The quarter was impacted by multiple one-offs including CAR-T impairment (Rs 1.3bn), Eftilagimod alfa impairment (Rs 914mn), and VAT liability provision (Rs 1.1bn). The Board recommended a dividend of Rs 8 per share and appointed Deloitte Haskins & Sells as new statutory auditors. North America revenues dropped 51% YoY due to Lenalidomide challenges, while India and Emerging Markets showed strong growth.
Significant profit decline and margin compression due to multiple exceptional items and generic drug pricing pressures, particularly in North America, may weigh on the stock near-term despite dividend announcement and auditor change.